Departments of aMolecular Biotechnology and Health Science and bMedical Sciences, University of Torino, Torino, Italy

Correspondence: Giovanni Camussi, M.D., Department of Medical Sciences, University of Torino, Corso Dogliotti 14, I-10126 Torino, Italy. Telephone: 390116709588; E-Mail: giovanni. camussi@unito.it
Received July 16, 2014; accepted for publication September 19, 2014; first published online in SCTM EXPRESS October 29, 2014.
©AlphaMed Press 1066-5099/2014/$20.00/0
http://dx.doi.org/ 10.5966/sctm.2014-0142
Concise Review: Different Mesenchymal Stromal/Stem Cell Populations Reside in the Adult Kidney
STEFANIA BRUNO,a GIULIA CHIABOTTO,b GIOVANNI CAMUSSIb
Key Words. Kidney x Stem cells x Tissue resident mesenchymal stem cells x Glomeruli
ABSTRACT
During fetal life, mesenchymal stromal/stem cells (MSCs) surround glomeruli and tubules and con- tribute to the development of the renal interstitium by secretion of growth factors that drive nephron differentiation. In the adult, an MSC-like population has been demonstrated in different compart- ments of human and murine nephrons. After injury, these cells might provide support for kidney re- generation by recapitulating the role they have in embryonic life. In this short review, we discuss the evidence of an MSC presence within the adult kidney and their potential contribution to the turnover ofrenalcellsandinjuryrepair. STEMCELLSTRANSLATIONALMEDICINE2014;3:1451–1455
INTRODUCTION
Multipotent mesenchymal stromal/stem cells (MSCs) are defined, according to the International Society for Cellular Therapy, on the basis of their ability to adhere to plastic, self-replicate, differentiate into mesodermal lineages (i.e., osteocytes, chondro- cytes, adipocytes), and express specific surface markers (CD105, CD73, and CD90) [1] and by their immunomodulatory capacity and low immunoge- nicity [2]. MSCs might have potential therapeutic applications in regeneration after injury of differ- ent organs (e.g., heart, kidneys, lungs, and liver), and they are currently being used in clinical trials for treating a wide range of diseases (available at: http://www.clinicaltrials.gov). MSCs exhibit mul- tidifferentiation capacity in vitro, and are able to migrate to injured sites in vivo after systemic ad- ministration [3]. Moreover, an increasing amount of evidence has indicated that the beneficial effects of MSC treatment on tissue/organ injury in dif- ferent animal models can be mainly attributed to paracrine activities [4].
Historically, MSCs were first isolated from the bone marrow (BM), where they play a role in he- matopoiesis [5, 6]. Subsequently, MSCs were also isolated from other organs and tissues [7–9]. The present review focused on MSCs identified in mu- rine and human kidneys, in particular, from the glomeruli.
MSCS RESIDENT IN THE MURINE KIDNEY
During embryogenesis, an MSC population can be detected in the kidneys. This population, which surrounds developing glomeruli and tubules, secretes growth factors that drive nephron differ- entiation [10]. Moreover, MSCs contribute to the
development of the renal interstitium [11]. In the event of kidney injury, interstitial cells might pro- vide support for kidney regeneration by assuming an immature phenotype and, thus, recapitulating the role performed during embryonic life [12]. Sev- eral years ago, using a method developed for cul- turing MSCs from the bone marrow, Plotkin and Goligorsky were able to isolate a clone of MSCs (termed “MSCs-E4”) from adult murine kidneys with characteristics similar to embryonic stromal cells [13]. This cell population was characterized by a phenotype (CD44, CD73, Sca-1 positivity) and a gene expression profile similar to that of mesenchymal renal embryonic cells. MSCs-E4 were shown to support angiogenesis and tubulo- genesis in vitro and were able to differentiate along multiple mesodermal lineages, including adipocytes, osteocytes, smooth muscle cells, and endothelial cells. Moreover, in hypoxic conditions, MSCs-E4 differentiated into fibroblast-produced erythropoietin [13]. When MSCs-E4 were subcaps- ularly injected after ischemia and reperfusion renal injury (IRI), they were able to migrate throughout the cortex and medulla and reached the papillary compartment [13]. These adult renal MSCs had the propensity to lodge at perivascular locations in the cortex and medulla [14] and remained in the interstitium without evidence of integration in- to glomeruli or tubules. This type of stromal pop- ulation capable of interacting with endothelial and epithelial cells could be important for renal homeostasis and repair after injury. When injected intravenously into IRI mice, MSCs-E4 engrafted the ischemic kidney and promoted tubular regenera- tion and functional recovery [15].
Another group of researchers described a pop- ulation of stem cells, resident in the renal intersti- tial space in close proximity to tubules, that were
STEM CELLS TRANSLATIONAL MEDICINE 2014;3:1451–1455 www.StemCellsTM.com ©AlphaMed Press 2014
Tissue-Specific Progenitor and Stem Cells
TISSUE-SPECIFIC PROGENITOR AND STEM CELLS

1452
MSCs Resident in Kidney
specifically located at the renal papilla [16]. These so-called nontub- ular multipotent stem/progenitor cells were isolated by cell sorting using the Sca-1 antigen as a marker of stem cells and were CD45 negative. In addition, this cell population was positive for CD29 and vimentin and negative for cytokeratin. Although Sca-1+ cells showed minimal expression of the surface markers typically expressed by bone marrow MSCs, they were able to differentiate into mesodermal cell lineages, such as osteocytes, chondrocytes, adipocytes, and myocytes, and into neural cells. Moreover, when the Sca-1+ cells were directly injected into renal parenchyma after IRI, they differentiated into epithelial tubular cells, thus contribut- ing to renal repair. Renal Sca-1+ cells displayed an immunomodu- latory capacity in vitro, confirming their mesenchymal nature [16]. The presence of an MSC-like population with immunomodulatory capacity was confirmed by another study [17]. The MSC-like pop- ulation described in that study, named “kidney-derived stromal cells” (KSCs), expressed Sca-1 antigen and MSC markers (i.e., CD29, CD44, CD105, vimentin) and were negative for hematopoietic (i.e., CD45, CD3, CD4, CD8) and tubular epithelial (i.e., cytokeratin, ZO-1, epithelial cell adhesion molecule) markers. In vitro, they had the capacity to differentiate into osteocytes and adipocytes [17]. Moreover, KSCs significantly reduced T cell proliferation, in a cell contact manner and were able to promote the differentiation of BM precursor into dendritic cells (DCs) refractory to maturation with lipopolysaccharide and producing increased interleukin-10 [17]. These cells were characterized by a phenotype with signifi- cant reduction of major histocompatibility complex class II and in- creased CD80 expression [17]. KSCs seem to act early during the differentiation of DCs from BM precursors to maintain DCs in an immature or “semimature” state associated with an immune- regulatory phenotype and self-tolerance induction [18].
More recently, Wang et al. reported the existence of renal MSC-like cells in mice [19]. This cell population was first detected by cytofluorimetric analyses of enzymatically digested murine kidneys. Renal MSC-like cells coexpressed CD44, CD117, CD105, and CD90 and represented about 5% of the total renal cells. After isolation of CD44+ cells by cell sorting and in vitro culture, they acquired the spindle-shape morphology typical of MSCs, lost the expression of CD117, maintained the expression of specific MSC markers (i.e., CD44, CD73, CD105, CD51) and expressed metanephric mesenchyme markers (i.e., Sox11, Foxd1, Id2, Eya4). Adult renal CD44+ MSCs were able to differentiate toward adi- pogenic, osteogenic, and smooth muscle cell lineages [19]. Re- markably, CD44+ MSCs were also able to differentiate into juxtaglomerular cells that contained renin in cytoplasmic gran- ules. When CD44+ MSCs were injected into the renal artery of mice preconditioned with a sodium-deficient diet, they success- fully engrafted in the kidneys, where they differentiated into renin-producing cells [19].
In the cited studies [13–17, 19], the murine renal resident cells with MSC characteristics were isolated by enzymatic digestion of the whole kidneys, with no distinction between the glomerular and tubular compartments. Investigations by da Silva Meirelles et al. [20] reported the isolation and characterization of an MSC population from isolated glomeruli deprived of Bowman’s capsu- les. Cells resembling the morphology of MSCs started outgrowth from plating glomeruli from day 3 or 4 after the beginning of cul- ture. Similar to MSCs obtained from entire kidneys and from other organs and tissues, the murine glomerular MSC population (gl- MSCs) expressed specific MSC markers, such as CD29, CD44, and CD90, and were negative for hematopoietic markers (i.e., CD45,
CD11b, CD13, CD19) and for the endothelial marker CD31. All the MSC populations obtained from different murine tissues and organs expressed a-smooth muscle actin (a-SMA). Moreover, the gl-MSC population described by da Silva Meirelles et al. [19] was able to undergo osteogenic and adipogenic differentiation and showed deposition of a calcium-rich mineralized matrix and ac- quisition of intracellular lipid droplets. In particular, gl-MSCs were able to differentiate more efficiently into the osteogenic lineage than were the whole kidney-derived MSCs. gl-MSCs deposited a rich mineralized matrix even after 1 week of culture with osteo- genic medium.
MSCS RESIDENT IN THE HUMAN KIDNEY
Different populations of progenitors/stem cells have been iden- tified in the adult kidney in humans. In particular, in human adult kidneys, the presence of resident progenitors/stem cells express- ing the CD133 stem cell marker has been detected in the tubular compartment, in Bowman’s capsules, and, more recently, in the papilla [21–24]. A possible role exists for neural-cell adhesion mol- ecule 1 (NCAM1) expression in the identification and function of human renal stem cells. NCAM1 has been shown to be expressed during embryonic kidney development [25] but not in the adult kidney. When human adult kidney epithelial cells were cultured, they all expressed CD133 and CD24, and a particular subpopula- tion (16% 6 9% of the total population) also showed re- expression of NCAM1 [26]. Sorted NCAM1-positive cells also expressed early nephron progenitor markers (e.g., Pax-2, WT1) and mesenchymal markers (e.g., vimentin) and displayed reduced E-cadherin expression. When NCAM1+ cells were cultured in the presence of conditioned medium produced by fetal renal cells, they differentiated into mesenchymal (adipogenic and osteo- genic) lineages and retained the capacity to generate epithelial kidney spheres [26]. Depletion of NCAM1+ cells from kidney ep- ithelial cells by specific anti-NCAM antibody treatment resulted in the loss of stemness properties both in vitro and in vivo [26], in- dicating the relevant role of NCAM1+ cells in renal regeneration.
To our knowledge, no research has described the isolation of MSCs from the whole human kidney or from the tubular compart- ment. Instead, the presence of an MSC population has been iden- tified in the glomerular compartment of the human kidney [27]. We reported that adult human glomeruli deprived of Bowman’s capsule by enzymatic digestion and mechanical passages (to avoid contamination of Bowman’s capsule–associated CD133+ progenitors) contain a resident MSC population. In our culture system, we found that cells outgrowing from the decapsulated glomeruli at early passages were composed of two distinct pop- ulations of CD133+CD146+ and CD1332CD146+ cells. The popu- lation coexpressing CD133 and CD146 showed an endothelial commitment and were also positive for the expression of specific endothelial markers, such as CD31 and von Willebrand factor, and were not able to give rise to a clonal population in vitro or to differ- entiate into specific mesodermal lineages. The CD1332CD146+ cells were the only cells that were outgrown from the glomeruli that had survived after four cell culture passages, and a subpopu- lation of cells was able to generate clonal long-term cultures of human glomerular MSCs (hgl-MSCs). This population expressed typical MSC markers (i.e., CD29, CD44, CD166, CD73, CD90, CD105, CD146, vimentin, and nestin) and did not express hema- topoietic markers (i.e., CD34, CD45). Moreover, hgl-MSC expressed typical markers of kidney stem cells, such as CD24 [22, 28] and Pax-2,
©AlphaMed Press 2014
STEM CELLS TRANSLATIONAL MEDICINE

Bruno, Chiabotto, Camussi 1453
Table 1. Characteristics and in vitro and in vivo properties of MSC-like populations obtained from human and murine adult kidney In vitro
Variable Origin
Nontubular Murine Sca-1+ Lin2
multipotent stem/ progenitor cells
Kidney part
Enzymatic digestion of whole kidney
Enzymatic digestion of whole kidney
Glomeruli
Isolation technique
Sca-1+ cells isolated with magnetic microbeads
CD44+ cells isolated with cell sorting
Plating glomeruli deprived of Bowman’s capsules
Phenotype
Sca-1+, CD29+, CD452, vimentin+
CD44+, CD73+, CD105+, CD51+
CD146+, CD29+, CD44+, CD166+, CD73+, CD90+, CD105+, CD146+, CD24+, Pax-2+, vimentin+, nestin+
differentiation
Osteocytes, chondrocytes, adipocytes, myocytes, neural cells
Osteocytes, adipocytes, smooth muscle cells, juxtaglomerular cells
Osteocytes, chondrocytes, adipocytes, endothelial cells, podocytes, mesangial cells
In vivo experiments
References
MSC-E4 Murine Enzymatic Culture conditions CD44+, CD73+, digestion of to obtain MSCs Sca-1+
wholekidney frommurine bone marrow
Osteocytes, adipocytes, smooth muscle cells, endothelial cells, EPO-producing cells
IRI mice: subscapular or intravenously injected MSCs favor renal regeneration without integration into tubules
or glomeruli
13–15
Kidney-derived Murine Enzymatic Sca-1+cells stromal cells digestion of obtained from wholekidney kidney-derived
spheres
Sca-1+,CD29+, CD44+, CD105+, vimentin+
Osteocytes, adipocytes
Not tested 17
CD44+ MSCs
Murine
IRI mice: MSCs 16 injected into renal
parenchyma
differentiate into
epithelial tubular cells
MSCs injected into 19 mice preconditioned
with a sodium-deficient
diet differentiated into renin-producing cells
Not tested 27
Glomerular MSCs Murine Glomeruli Plating glomeruli CD29+, CD44+, Osteocytes, adipocytes Not tested 20 deprived of CD90+, a-SMA+
Bowman’s capsules
hgl-MSCs Human
Abbreviations: EPO, erythropoietin; hgl-MSC, human glomerular mesenchymal stem cell; IRI, ischemia reperfusion injury; MSC, mesenchymal stem cell.
a transcription factor expressed by stem cells present in the meta- nephric mesenchyme [29].
Because one of the major defining characteristics of MSCs is their ability to differentiate into multiple mesenchymal lineages, the capacity of hgl-MSCs to differentiate into specific connective tissue cells was evaluated. hgl-MSCs efficiently underwent oste- ogenic differentiation and, when cultured in adipocyte medium, were able to generate cells containing lipid droplets. In addition, hgl-MSCs were able to differentiate into chondrocytes. After 28 days of culture in specific nonadhesive conditions in the presence of transforming growth factor b3, hgl-MSC pellets were positive to staining with safranin O and Alcian blue, which is characteristic of chondrocytic differentiation [27].
The capacity of hgl-MSCs to differentiate, under appropriate culture conditions, into specific cell populations present in the glomeruli (i.e., endothelial cells, podocytes, mesangial cells) was also evaluated. Endothelial differentiation was obtained by cultur- ing hgl-MSCs in the presence of vascular endothelial growth factor. After 3 weeks of culture in these conditions, hgl-MSCs had lost the expression of mesenchymal markers and had started to express specific endothelial markers, such as CD105, KDR, CD34, and CD31, and to acquire the capacity to form capillary-like structures in vitro in the presence of Matrigel (BD Biosciences, San Diego, CA, http://www.bdbiosciences.com). When hgl-MSCs were cultured in the presence of platelet-derived growth factor BB and transform- ing growth factor b1, the cells acquired a mesangial-like phenotype and expressed a-SMA and angiotensin-2 receptor 1. Moreover, in
these conditions, hgl-MSCs acquired the ability to change their shape when stimulated with angiotensin-2, compatible with cell contraction. When hgl-MSCs were cultured for 3 weeks in the pres- ence of transretinoic acid, they differentiated into podocyte-like cells and expressed typical markers, such as cytokeratin, podocin, nephrin, and synaptopodin (Table 1) [27].
The mesenchymal nature of hgl-MSCs was also confirmed by a study that evaluated their immunomodulatory capacity [27]. In particular, hgl-MSCs were able to inhibit proliferation of phytohemagglutinin-stimulated peripheral blood mononu- clear cells, similar to BM-MSCs.
Another important issue was demonstrating the renal origin of the isolated hgl-MSCs. Therefore, a population of hgl-MSCs was isolated from glomeruli of an explanted kidney from a male donor transplanted into a female recipient [27]. To determine whether the hgl-MSCs were derived from the bone marrow of the recipient or were resident in the transplanted kidney, the presence of the Y chromosome was detected at different culture passages. No female karyotype was found at the various culture passages, indicating that the hgl-MSCs were not derived from the bone mar- row of the recipient (female) but, rather, represented a popula- tion resident in the glomeruli of the donor kidney (male) [27].
These data have demonstrated the presence of a population of resident multipotent progenitors in the adult human decapsulated glomeruli, with mesenchymal characteristics and the potential to contribute to the turnover of the different glomerular-specific cell types.
www.StemCellsTM.com
©AlphaMed Press 2014

1454
MSCs Resident in Kidney
PERICYTES: MSCS RESIDENT IN CAPILLARY WALLS?
Pericytes are vascular mural cells that stabilize vessels by modu- lating the endothelial phenotype and the extracellular matrix composition. A single marker for pericyte isolation and character- ization has not been found. Similar to MSCs, pericytes are also cur- rently characterized by coexpression of different markers, such as a-SMA, desmin, platelet-derived growth factor receptor-b, neuron-glial 2, CD146, CD73, and CD248 [30]. Some of these markers (i.e., CD146, CD73) are also expressed by MSCs and/or by endothelial cells (CD146). Pericytes and MSCs not only have common markers, but pericytes also exhibit mesodermal multili- neage differentiation potential [31]. In particular, pericytes can differentiate into smooth muscle cells, adipocytes, chondrocytes, and osteoblasts [31, 32]. Within the glomeruli of the kidney, pericytes are known as mesangial cells and provide support for glomerular capillaries, control for glomerular filtration, and modulate the local injury response by proliferation and matrix remodeling. In addition, mesangial cells, similar to MSCs, are able to modulate innate and adaptive responses by acting as local im- mune modulators [33].
MSCs have been tested in different animal models of acute kidney injury (AKI) and chronic kidney disease (CKD). In AKI, MSCs have shown protective and regenerative effects [34–36]. In CKD, some experimental evidence has indicated that MSC treatment reduced fibrosis and ameliorated renal function [37–41]. How- ever, MSC therapy for CKD remains to be investigated in more de- tail. In CKD rodent models, MSC treatment showed a beneficial effect [37–41], but in large animal models (e.g., sheep with ische- mia and reperfusion renal injury), MSCs did not exhibit reparative or protective properties [42]. Pericytes/mesangial cells share some important characteristics with MSCs and could potentially be considered as resident renal stem/progenitor cells, although pericytes/mesangial cells have not yet been tested in animal mod- els of kidney injuries. Moreover, pericytes were recently identi- fied as a source of collagen I-producing cells in kidney disease [43], and pericytes can differentiate into myofibroblasts, causing scar tissue with progressive fibrosis and deterioration of renal
function [44, 45]. These data indicate that pericytes might be a tar- get for antifibrotic therapy. Before developing possible clinical interventions using pericytes as targets for therapy or as thera- peutic agents, it is necessary to better understand the biology and behavior of these cells. In particular, it is necessary to study the capacity of pericytes to respond to tissue injury and to act as progenitor cells, facilitating the regenerative process and not the fibrotic response.
CONCLUSION
Different MSC-like populations have been demonstrated to be present in both human and murine kidneys. These cells have been found in the glomeruli and interstitium and have multipotent characteristics similar to bone marrow-resident MSCs. In partic- ular, human and murine renal MSCs shared with bone marrow MSCs the multidifferentiation capacity toward specific mesen- chymal lineages, such as the adipocytic, osteocytic, and chondro- cytic lineages [13, 16, 19, 20] and immunomodulatory properties [16, 17, 27]. Moreover, renal resident MSCs were shown to differ- entiate, under appropriate culture conditions, into specific renal cell types, such as erythropoietin-producing fibroblasts [13], jux- taglomerular cells containing renin granules [19], podocytes, and mesangial cells [27]. Although renal resident MSCs have been shown to play a defined role in kidney development, little is known about their contribution to cell turnover and repair in the adult kidney.
AUTHOR CONTRIBUTIONS
S.B. and G. Chiabotto: conception and design, manuscript writing; G. Camussi: conception and design, financial support, manuscript writing.
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
The authors indicate no potential conflicts of interest.
REFERENCES
1 Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mes- enchymal stromal cells. The International Soci- ety for Cellular Therapy position statement. Cytotherapy 2006;8:315–317.
2 Krampera M, Galipeau J, Shi Y et al. Immu- nological characterization of multipotent mesen- chymal stromal cells–The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013;15:1054–1061.
3 Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284: 143–147.
4 Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98:1076–1084.
5 Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71–74.
6 Me ́ndez-Ferrer S, Michurina TV, Ferraro F et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829–834.
7 Tobita M, Mizuno H. Adipose-derived stem cells and periodontal tissue engineering. Int J Oral Maxillofac Implants 2013;28:e487–e493.
8 Hilkens P, Gervois P, Fanton Y et al. Effect of isolation methodology on stem cell proper- ties and multilineage differentiation potential of human dental pulp stem cells. Cell Tissue Res 2013;353:65–78.
9 Indumathi S, Harikrishnan R, Mishra R et al. Comparison of feto-maternal organ de- rived stem cells in facets of immunophenotype, proliferation and differentiation. Tissue Cell 2013;45:434–442.
10 Cullen-McEwen LA, Caruana G, Bertram JF. The where, what and why of the developing renal stroma. Nephron Exp Nephrol 2005;99: e1–e8.
11 Alcorn D, Maric C, McCausland J. Devel- opment of the renal interstitium. Pediatr Neph- rol 1999;13:347–354.
12 Herzlinger D. Renal interstitial fibrosis: Remembrance of things past? J Clin Invest 2002;110:305–306.
13 Plotkin MD, Goligorsky MS. Mesenchy- mal cells from adult kidney support angiogene- sis and differentiate into multiple interstitial cell
types including erythropoietin-producing fibro- blasts. Am J Physiol Renal Physiol 2006;291: F902–F912.
14 Ratliff BB, Singh N, Yasuda K et al. Mesen- chymal stem cells, used as bait, disclose tissue binding sites: A tool in the search for the niche? Am J Pathol 2010;177:873–883.
15 Chen J, Park HC, Addabbo F et al. Kidney- derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kidney Int 2008;74:879–889.
16 Dekel B, Zangi L, Shezen E et al. Isolation and characterization of nontubular Sca-1+Lin2 multipotent stem/progenitor cells from adult mouse kidney. J Am Soc Nephrol 2006;17: 3300–3314.
17 Huang Y, Johnston P, Zhang B et al. Kidney-derived stromal cells modulate den- dritic and T cell responses. J Am Soc Nephrol 2009;20:831–841.
18 Lutz MB, Schuler G. Immature, semi- mature and fully mature dendritic cells: Which signals induce tolerance or immunity? Trends Immunol 2002;23:445–449.
19 Wang H, Gomez JA, Klein S et al. Adult re- nal mesenchymal stem cell-like cells contribute
©AlphaMed Press 2014
STEM CELLS TRANSLATIONAL MEDICINE

Bruno, Chiabotto, Camussi 1455
to juxtaglomerular cell recruitment. J Am Soc Nephrol 2013;24:1263–1273.
20 da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in vir- tually all post-natal organs and tissues. J Cell Sci 2006;119:2204–2213.
21 Bussolati B, Bruno S, Grange C et al. Iso- lation of renal progenitor cells from adult hu- man kidney. Am J Pathol 2005;166:545–555.
22 Sagrinati C, Netti GS, Mazzinghi B et al. Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J Am Soc Nephrol 2006; 17:2443–2456.
23 Ward HH, Romero E, Welford A et al. Adult human CD133/1(+) kidney cells isolated from papilla integrate into developing kidney tubules. Biochim Biophys Acta 2011;1812: 1344–1357.
24 Bussolati B, Moggio A, Collino F et al. Hypoxia modulates the undifferentiated phe- notype of human renal inner medullary CD133+ progenitors through Oct4/miR-145 balance. Am J Physiol Renal Physiol 2012;302:F116– F128.
25 Harari-Steinberg O, Metsuyanim S, Omer D et al. Identification of human nephron pro- genitorscapableofgenerationofkidneystruc- tures and functional repair of chronic renal disease. EMBO Mol Med 2013;5:1556–1568.
26 Buzhor E, Omer D, Harari-Steinberg O et al. Reactivation of NCAM1 defines a subpop- ulation of human adult kidney epithelial cells with clonogenic and stem/progenitor proper- ties. Am J Pathol 2013;183:1621–1633.
27 Bruno S, Bussolati B, Grange C et al. Iso- lation and characterization of resident mesen- chymal stem cells in human glomeruli. Stem Cells Dev 2009;18:867–880.
28 Challen GA, Martinez G, Davis MJ et al. Identifying the molecular phenotype of renal progenitor cells. J Am Soc Nephrol 2004;15: 2344–2357.
29 Oliver JA, Barasch J, Yang J et al. Meta- nephric mesenchyme contains embryonic renal stem cells. Am J Physiol Renal Physiol 2002;283: F799–F809.
30 Stefanska AM, Peault B, Mullins JJ. Renal pericytes: Multifunctional cells of the kidneys.. Pflugers Arch 2013;465:767–773.
31 Crisan M, Yap S, Casteilla L et al. A peri- vascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3: 301–313.
32 Covas DT, Panepucci RA, Fontes AM et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 2008;36:642–654.
33 Schlo ̈ndorff D, Banas B. The mesangial cell revisited: No cell is an island. J Am Soc Neph- rol 2009;20:1179–1187.
34 Morigi M, Imberti B, Zoja C et al. Mesen- chymal stem cells are renotropic, helping to re- pair the kidney and improve function in acute renalfailure.JAmSocNephrol2004;15:1794– 1804.
35 Herrera MB, Bussolati B, Bruno S et al. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004;14:1035–1041.
36 Duffield JS, Bonventre JV. Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after is- chemic injury. Kidney Int 2005;68:1956–1961.
37 Semedo P, Correa-Costa M, Antonio Cenedeze M et al. Mesenchymal stem cells
attenuate renal fibrosis through immune modula- tion and remodeling properties in a rat remnant kidney model. STEM CELLS 2009;27:3063–3073.
38 ChoiS,ParkM,KimJetal.Theroleof mesenchymal stem cells in the functional im- provement of chronic renal failure. Stem Cells Dev 2009;18:521–529.
39 Villanueva S, Carren~o JE, Salazar L et al. Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure. Clin Sci (Lond) 2013;125:199–210.
40 Alfarano C, Roubeix C, Chaaya R et al. Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine- immunosuppressed rats. Cell Transplant 2012; 21:2009–2019.
41 Villanueva S, Ewertz E, Carrio ́n F et al. Mesenchymal stem cell injection ameliorates chronic renal failure in a rat model. Clin Sci (Lond) 2011;121:489–499.
42 Behr L, Hekmati M, Lucchini A et al. Eval- uation of the effect of autologous mesenchymal stem cell injection in a large-animal model of bi- lateral kidney ischaemia reperfusion injury. Cell Prolif 2009;42:284–297.
43 Stefan ́skaA,Pe ́aultB,MullinsJJ.Renal pericytes: Multifunctional cells of the kidneys. Pflugers Arch 2013;465:767–773.
44 Humphreys BD, Lin S-L, Kobayashi A et al. Fate tracing reveals the pericyte and not epithe- lial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010;176:85–97.
45 Lin SL, Kisseleva T, Brenner DA et al. Peri- cytes and perivascular fibroblasts are the pri- mary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008;173:1617–1627.
www.StemCellsTM.com
©AlphaMed Press 2014